Mobile

Long-term Follow-up Study for Cardiac Safety in the Patients with Breast Cancer Who Have Completed the Main Study

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-005663-17

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to observe the incidence of symptomatic congestive heart failure (CHF) NYHA class II,III and IV and asymptomatic LVEF decrease in patients who participated in the SB3-G31-BC Study and treated with SB3 ( proposed trastuzumab biosimilar) or Herceptin® as neoadjuvant and adjuvant treatment.

Critère d'inclusion

  • Subjects with primary HER2 positive early or locally advanced breast cancer, who have completed the study treatment of SB3-G31-BC

Liens